Tumor necrosis factor inhibitors - State of knowledge

Archives of Medical Science

Volumn 10, Issue 6, 2014, Pages 1175-1185

  Lis, Krzysztof ^a   Kuzawińska, Olga ^a   Bałkowiec Iskra, Ewa ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Adverse effect; Biologic agents; Rheumatic disease; Tumor necrosis factor inhibitors

Indexed keywords

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; CONGESTIVE HEART FAILURE; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG SAFETY; GRANULOMATOSIS; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; JUVENILE RHEUMATOID ARTHRITIS; META ANALYSIS (TOPIC); NEOPLASM; OFF LABEL DRUG USE; PREGNANCY; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SKIN DISEASE;

EID: 84920040469     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2014.47827     Document Type: Article

References (65)

1. Pennica D, Nedwin GE, Hayfick JS, et al. Human tumor necrosis factor: precursor structure, expression and ho-mology to lymphotoxin. Nature 1984; 312: 724-9.
2. Pappa S, Hatzistilianou M, Kouvatsi A, et al. Tumour necrosis factor gene polymorphisms and migraine in Greek children. Arch Med Sci 2010; 6: 430-7.
3. Mielczarek-Palacz A, Kondera-Anasz Z, Sikora J. Higher serum levels of tumour necrosis factor and its soluble receptors are associated with ovarian tumours. Arch Med Sci 2012; 8: 848-53.
4. Yildiz Y, YaylIm-Eraltan I, Arikan S, Ergen A, Küçücük S, Isbir T. Is there any correlation between TNF-related apoptosis-inducing ligand (TRAIL) genetic variants and breast cancer? Arch Med Sci 2010; 6: 932-6.
5. Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM. Isolated limb perfusion with melphan and tumor necrosis factor for advanced melanoma and soft-tisssue sarkoma. Ann Surg Oncol 2007; 14: 230-8.
6. http://www.emea.europa.eu/docs/en-GB/document-library/EPAR-Scientifc-Discussion/human/000206/WC500052375.pdf
7. No authors listed. Biologic drugs set to top 2012 sales. Nature Medicine 2012; 18: 636.
8. Alexopoulou L, Kranidioti K, Xanthoulea S, et al. Trans-bembrane TNF protects mutant mice against intracellu-lar bacterial infections, chronic infammation and auto-immunity. Eur J Immunol 2006; 36: 2768-80.
9. Tansey MG, Szymkowski DE. The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Discov Today 2009; 14: 1082-8.
10. Buks J, Wilczak M, Rzymski P, Opala T. Do soluble p55 and p75 TNF-receptor concentrations play a role in women with primary sterility? Arch Med Sci 2010; 6: 264-9.
11. Grell M. Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF. J In-famm 1995; 47: 8-17.
12. Grell M, Wajant H, Zimmermann G, Scheurich P. The type I receptor (CD 120a) is the high-afnity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 1998; 95: 570-5.
13. Naude PJW, den Boer JA, Luiten PG, Eisel LM. Tumor necrosis factor receptor cross-talk. FEBS J 2011; 278: 888-98.
14. Kafrouni MI, Brown GR, Thiele DL. The role of TNF-TN-FR2 interactions in generation of CTL responses and clearance of hepatic adenowirus infection. J Leukoc Biol 2003; 74: 564-71.
15. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanism of action: a comprehensive review. Pharmacol Therap 2008; 117: 244-79.
16. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic efects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor-expressing cells. Arth Rheum 2008; 58: 1248-57.
17. Feldmann M, Maini RN. Anti-TNF therapy from rationale to standard of care: what lesson has it taught us? J Immunol 2010; 185: 791-4.
18. Prajapati R, Plant D, Barton A. Genetic and genomic predictors of anti-TNF response. Pharmacogenomics 2011; 12: 1571-85.
19. Maneiro JR, Salgado E, Gomez-Reino JJ, Carmona L. Ef-cacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review. Semin Arthitis Rheum 2012; 42: 89-103.
20. Utz J P, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoid-osis. Chest 2003; 124: 177-85.
21. Tong D, Manolios N, Howe G, Spencer D. New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. Int Med J 2012; 42: 89-94.
22. Rifkin LM, Birnbaum AD, Goldstein DA. TNF inhibition for ophtalmic indications: current status and outlook. BioDrugs 2013; 27: 347-57.
23. Karampetsou M P, Liossis SNC, Sfkakis PP. TNF antagonists beyond approved indications: stories of success and prospects for the future. QJMed 2010; 103: 917-28.
24. Sfkakis P P, Grigoropoulos V, Emfetzoglou I, et al. In-fiximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care 2010; 33: 1523-8.
25. Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumor necrosis factor inhibitors. Acta Derm Venerol 2009; 89: 595-600.
26. Patel R, Cafardi JM, Patel N, Sami N, Cafardi JA. Tumor necrosis factor biologics beyond psoriasis in dermatology. Expert Opin Biol Ther 2011; 11: 1341-59.
27. Wolbink GJ, Vis M, Lems W, et al. Development of antiin-fiximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711-5.
28. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Co-chrane overview. Cochrane Database Syst Rev 2011; 2: CD008794.
29. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the efect of infiximab therapy. Arthritis Rheum 2004; 50: 372-9.
30. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006; 43: 717-22.
31. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy. Arth Rheum 2009; 60: 1884-94.
32. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301: 737-44.
33. Balkwill F. Tumor necrosis factor and cancer. Nat Rev Cancer 2009; 9: 361-71.
34. Balkwill F, Mantovani A. Cancer and infammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 2010; 87: 401-6.
35. Rodgers M, Epstein D, Bojke L, et al. Etanercept, infix-imab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011; 15: 1-329.
36. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998; 317: 180-1.
37. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infiximab using patient level data. Pharmacoepidemiol Drug Saf 2011; 20: 119-30.
38. Ruiz Garcia V, Jobanputra P, Burls A, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Co-chrane Database Syst Rev 2011; 2: CD007649
39. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010; 1: CD008341.
40. Moulis G, Sommet A, Bene J, et al. Cancer risk of anti-TNF at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLOS One 2012; 7: 1-7.
41. Moulis G, Sommet A, Lapeyre-Mestre M. Mortality rates among patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: comment on the article by Simard et al. Arthitis Rheum 2013; 65: 1670-1.
42. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70: 1895-904.
43. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Eng J Med 1991; 325: 467-72.
44. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identifed in multiple sclerosis brain. J Exp Med 1989; 170: 607-12.
45. Rieckmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor messenger RNA expression in patients with re-lapsing-remmiting multiple sclerosis is associated with disease activity. Ann Neurol 1995; 37: 82-8.
46. Rieckmann P, Albrech M, Kitze B, et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994; 44: 1523-6.
47. Arnason BG. TNF neutralization in MS: results of a randomized placebo-controlled multicenter study. Neurology 1999; 53: 457-65.
48. Schif MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 889-94.
49. Schaible TF. Long term safety of infiximab. Can J Gastro-enterol 2000; 14: 29-32.
50. Aringer M, Smolen JS. Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun Rev 2012; 11: 321-5.
51. Bene J, Moulis G, Aufret M, Fessier C, Lefevre G, Gautier S. Tumor necrosis factor antagonists and alopecia: a case/non case in a Nationwide Pharmacovigilance Database. Arthitis Rheum 2012; 64: S788.
52. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Bio-logics Register. Ann Rheum Dis 2009; 68: 209-15.
53. Setoguchi S, Schneeweiss S, Avorn J, et al. Tumor necrosis factor-(alpha) antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 2008; 156: 336-41.
54. Curtis JR, Kramer JM, Martin C, et al. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. Rheumatology 2007; 46: 1688-93.
55. Katz JA, Antoni C, Keenan G F, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infiximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99: 2385-92.
56. Yaser AM, Kuriya B, Orozco C, Cush JJ, Keystone EC. Can tumor necrosis factor inhibitors be safely used in pregnancy? J Rheumatol 2010; 37: 9-17.
57. Verstappen SMM, King Y, Watson KD, Symmons DPM, Hyrich KL. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 823-6.
58. Hallenbeck JM. The many faces of tumor necrosis factor in Stoke. Nat Med 2002; 8: 1363-8.
59. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor alpha increases both in the brain and in the cerebrospinal fuid form parkinso-nian patients. Neurosci Lett 1994; 165: 208-10.
60. Mehlhorn G, Hollborn M, Schliebs R. Induction of cy-tokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci 2000; 18: 423-31.
61. Moss ML, Sklair-Tavron L, Nudelmann R. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol 2008; 4: 300-9.
62. Bałkowiec-Iskra E, Vermehren-Schmaedick A, Balko-wiec A. Tumor necrosis factor-alpha increases brain-derived neurotrophic factor expression in trigeminal ganglion neurons in an activity-dependent manner. Neuroscience 2011; 180: 322-33.
63. Biologic drugs set to top 2012 sales. Nat Med 2012; 18: 636.
64. Karampetsou M P, Liossis SNC, Sfkakis PP. TNF antagonists beyond approved indications: stories of success and prospects for the future. QJM 2010; 103: 917-28.
65. Patel R, Cafardi JM, Patel N, Sami N, Cafardi JA. Tumor necrosis factor biologics beyond psoriasis in dermatology. Expert Opin Biol Ther 2011; 11: 1341-59.